Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib

Oncology Reports

Volumn 31, Issue 2, 2014, Pages 835-841

  Wang, Huaqian ^a   Cui, Xiao Xing ^b   Goodin, Susan ^c   Ding, Ning ^b   Van Doren, Jeremiah ^b   Du, Zhiyun ^a   Huang, Mou Tuan ^b   Liu, Yue ^b   Cheng, Xiaodong ^d   Dipaola, Robert S ^c   Conney, Allan H ^a,b,c   Zheng, Xi ^a,b,c  

^a GUANGDONG UNIVERSITY OF TECHNOLOGY   (China)

^b RUTGERS UNIVERSITY   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^d TONGJI UNIVERSITY   (China)

Author keywords

Atorvastatin; Celecoxib; IL 6; Prostate cancer; Xenograft tumor

Indexed keywords

ANDROGEN; ATORVASTATIN; CELECOXIB; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 6; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASTRATION; CELL SURVIVAL; CYCLOOXYGENASE 2 INHIBITORS; DISEASE PROGRESSION; ENZYME INHIBITORS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INHIBITOR OF APOPTOSIS PROTEINS; INTERLEUKIN-6; MALE; MICE; MICE, SCID; PROSTATIC NEOPLASMS; PYRAZOLES; PYRROLES; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84892399974     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2885     Document Type: Article

References (37)

1. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott J, Taplin M, Vogelzang NJ, Wade JL III, Bennett CL, Scher HI; American Society of Clinical Oncology: Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 25: 1596-1605, 2007.
2. Devlin HL and Mudryj M: Progression of prostate cancer: multiple pathways to androgen independence. Cancer Lett 274: 177-186, 2009.
3. So A, Gleave M, Hurtado-Col A and Nelson C: Mechanisms of the development of androgen independence in prostate cancer. World J Urol 23: 1-9, 2005.
4. Schröder FH: Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms. Eur Urol 53: 1129-1137, 2008.
5. Chi KN, Bjartell A, Dearnaley D, Saad F, Schröder FH, Sternberg C, Tombal B and Visakorpi T: Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol 56: 594-605, 2009.
6. Pilat MJ, Kamradt JM and Pienta KJ: Hormone resistance in prostate cancer. Cancer Metastasis Rev 17: 373-381, 1998-1999.
7. Stein MN, Goodin S and Dipaola RS: Abiraterone in prostate cancer: a new angle to an old problem. Clin Cancer Res 18: 1848-1854, 2012.
8. Seruga B and Tannock IF: Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol 29: 3686-3694, 2011.
9. Farnier M and Davignon J: Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol 82: 3J-10J, 1998.
10. Malhotra HS and Goa KL: Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Drugs 61: 1835-1881, 2001.
11. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ and Calle EE: Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 16: 2213-2217, 2007.
12. Flick ED, Habel LA, Chan KA, et al: Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev 16: 2218-2225, 2007.
13. Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ, Presti JC Jr, Amling CL and Freedland SJ: Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 116: 3389-3398, 2010.
14. Abedinpour P, Baron VT, Welsh J and Borgström P: Regression of prostate tumors upon combination of hormone ablation therapy and celecoxib in vivo. Prostate 71: 813-823, 2011.
15. Dandekar DS, Lopez M, Carey RI and Lokeshwar BL: Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int J Cancer 115: 484-492, 2005.
16. Harris RE: Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17: 55-67, 2009.
17. Reddy BS, Wang CX, Kong AN, Khor TO, Zheng X, Steele VE, Kopelovich L and Rao CV: Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res 66: 4542-4546, 2006.
18. Zheng X, Cui XX, Gao Z, Zhao Y, Lin Y, Shih WJ, Huang MT, Liu Y, Rabson A, Reddy B, Yang CS and Conney AH: Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence. Cancer Prev Res 3: 114-124, 2010.
19. Zheng X, Cui XX, Avila GE, Huang MT, Liu Y, Patel J, Kong AN, Paulino R, Shih WJ, Lin Y, Rabson AB, Reddy BS and Conney AH: Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice. Clin Cancer Res 13: 5480-5487, 2007.
20. Hammacher A, Thompson EW and Williams ED: Interleukin-6 is a potent inducer of S100P, which is up-regulated in androgen-refractory and metastatic prostate cancer. Int J Biochem Cell Biol 37: 442-450, 2005.
21. Chen T, Wang LH and Farrar WL: Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 60: 2132-2135, 2000.
22. Kim O, Jiang T, Xie Y, Guo Z, Chen H and Qiu Y: Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells. Oncogene 23: 1838-1844, 2004.
23. Gazi MH, Gong A, Donkena KV and Young CY: Sodium selenite inhibits interleukin-6-mediated androgen receptor activation in prostate cancer cells via upregulation of c-Jun. Clin Chim Acta 380: 145-150, 2007.
24. Smith PC, Hobisch A, Lin DL, Culig Z and Keller ET: Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 12: 33-40, 2001.
25. Malinowska K, Neuwirt H, Cavarretta IT, Bektic J, Steiner H, Dietrich H, Moser PL, Fuchs D, Hobisch A and Culig Z: Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer 16: 155-169, 2009.
26. Lee SO, Lou W, Johnson CS, Trump DL and Gao AC: Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. Prostate 60: 178-186, 2004.
27. Wei X, Du ZY, Cui XX, Verano M, Mo RQ, Tang ZK, Conney AH, Zheng X and Zhang K: Effects of cyclohexanone analogues of curcumin on growth, apoptosis and NF-κB activity in PC-3 human prostate cancer cells. Oncol Lett 4: 279-284, 2012.
28. Zheng X, Chang RL, Cui XX, Avila GE, Hebbar V, Garzotto M, Shih WJ, Lin Y, Lu SE, Rabson AB, Kong AN and Conney AH: Effects of 12-O- tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice. Clin Cancer Res 12: 3444-3451, 2006.
29. Zheng X, Cui XX, Huang MT, Liu Y, Wagner GC, Lin Y, Shih WJ, Lee MJ, Yang CS and Conney AH: Inhibition of progression of androgen-dependent prostate LNCaP tumors to androgen independence in SCID mice by oral caffeine and voluntary exercise. Nutr Cancer 64: 1029-1037, 2012.
30. Hsu JC: Comparisons: Theory and Methods. Chapman and Hall, New York, NY, 1996.
31. Zhao L, Wientjes MG and Au JL: Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 10: 7994-8004, 2004.
32. Hirano T: The biology of interleukin-6. Chem Immunol 51: 153-180, 1992.
33. Michalaki V, Syrigos K, Charles P and Waxman J: Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 90: 2312-2316, 2004.
34. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H and Murai M: Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6: 2702-2706, 2000.
35. Altieri DC: Targeting survivin in cancer. Cancer Lett 332: 225-228, 2013.
36. Shariat SF, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM and Ashfaq R: Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 100: 751-757, 2004.
37. Costantino L and Barlocco D: STAT 3 as a target for cancer drug discovery. Curr Med Chem 15: 834-843, 2008.